Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Omnitarg pertuzumab: Phase II data

DNA said that in an open-label Phase II trial, Omnitarg monotherapy

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE